Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neuropathic Pain Second Indication Could Be Based On Single Trial – Cmte

Executive Summary

A second neuropathic pain indication could be approved based on one additional trial, providing the single trial was well-controlled and produced robust results, FDA's Anesthetic and Life Support Drugs Advisory Committee said May 16

You may also be interested in...



CDER Guidance Agenda 2004: Pregnancy, Pediatric Studies Are Priorities

FDA is planning several new guidances to refine recommendations for drug studies in children and pregnant women during 2004, the Center for Drug Evaluation & Research's guidance agenda for the coming year indicates

CDER Guidance Agenda 2004: Pregnancy, Pediatric Studies Are Priorities

FDA is planning several new guidances to refine recommendations for drug studies in children and pregnant women during 2004, the Center for Drug Evaluation & Research's guidance agenda for the coming year indicates

Neurontin Pain Claim Follows Cmte. Preference For Individual Etiologies

Pfizer's Neurontin postherpetic neuralgia indication closely follows a recent advisory committee recommendation that indications for individual etiologies of neuropathic pain would be preferable to a broad claim

UsernamePublicRestriction

Register

PS039869

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel